2025年12月7日，国家医疗保障局正式公布《国家基本医疗保险、生育保险和工伤保险药品目录（2025 年）》（以下简称"国家医保目录"）。重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"）宣 布，其自主研发的1类生物创新药——赛立奇单抗注射液（金立希®）成功纳入国家医保目录。新版国 家医保目录将于2026年1月1日起正式实施。 源头创新，国产原研突破垄断 作为一家专注于全链条抗体药物研发与产业化的创新型生物制药企业，智翔金泰始终坚持以科技创新为 核心驱动力，聚焦未被满足的重大临床需求，致力于为患者提供高质量、可负担的治疗选择。 赛立奇单抗注射液是智翔金泰基于独有的双载体噬菌体呈现技术平台研发的重组全人源抗IL-17A单克隆 抗体。该药物通过特异性结合血清中的IL-17A细胞因子，阻断IL-17A与IL-17RA的结合，抑制炎症的发 生和疾病的发展。作为我国首款全人源抗IL-17A单克隆抗体，赛立奇单抗自2024年8月获批上市以来， 已陆续获批用于治疗中、重度斑块状银屑病和强直性脊柱炎（放射学阳性中轴型脊柱关节炎）两大适应 症，打破了外资药企在该靶点治疗药物的垄断局面，为中国患者提供了与国际水平接轨的高质 ...

Core Insights - A-share companies reported stable growth in 2024, with total revenue reaching 71.92 trillion yuan and net profit at 5.21 trillion yuan, with 75% of companies profitable and 48% showing year-on-year profit growth [1] Group 1: Industry Performance - The agriculture, forestry, animal husbandry, and fishery sectors saw significant profit growth, with a net profit increase of 1447%, primarily due to falling feed prices benefiting livestock companies [1] - The electronic and non-bank financial sectors led revenue growth, each with approximately 17% increase [1] Group 2: Company Highlights - 117 companies achieved revenue exceeding 100 billion yuan, marking a historical high, with 7 companies surpassing 1 trillion yuan in revenue [1] - BYD's revenue reached 777.1 billion yuan in 2024, a 29% increase, surpassing Tesla's annual revenue for the first time [2] - 65 companies doubled their revenue in 2024, with Zhixiang Jintai leading at a 2384.1% increase due to a newly approved drug [3] Group 3: Profitability - 77 companies reported net profits exceeding 10 billion yuan, with 10 companies surpassing 100 billion yuan, mainly in the banking and insurance sectors [6] - Zhengdan Co. achieved a net profit growth rate of nearly 120 times, driven by soaring prices of its main product [6][7] Group 4: R&D Investment - A-share companies collectively invested 1.6 trillion yuan in R&D in 2024, with 22 companies exceeding 10 billion yuan in R&D spending [8] - BYD led R&D investment with 54.16 billion yuan, contributing to significant technological advancements [8]